目的 探討胰膽炎合劑聯(lián)合注射用生長抑素治療急性胰腺炎的臨床療效。方法 選取2019年4月—2021年6月在南陽市中心醫(yī)院就診的83例急性胰腺炎患者，根據(jù)隨機(jī)數(shù)字表法將所有患者分為對照組（40例）和治療組（41例）。對照組靜脈滴注注射用生長抑素，3 mg加入50 mL生理鹽水中，靜脈持續(xù)泵注，速度為250 μg/h，1次/d。治療組在對照組基礎(chǔ)上口服胰膽炎合劑，1袋/次，2次/d。兩組患者連續(xù)治療7 d。觀察兩組患者臨床療效，比較兩組癥狀消失時間，血清脂肪酶、淀粉酶、高遷移率族蛋白B1（HMGB1）、二胺氧化酶（DAO）、白細(xì)胞介素-35（IL-35）水平。結(jié)果 治療后，治療組總有效率為92.68%，對照組總有效率為75.00%，組間有明顯差異（P<0.05）。治療后，治療組的高熱、腹痛、腹脹、惡心、嘔吐消失時間短于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的脂肪酶、淀粉酶水平顯著降低（P<0.05），且以治療組脂肪酶、淀粉酶水平降低更明顯（P<0.05）。治療后，兩組的HMGB1、DAO、IL-35水平明顯減少（P<0.05）；且治療組治療后的HMGB1、DAO、IL-35水平低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 胰膽炎合劑聯(lián)合注射用生長抑素治療急性胰腺炎的療效確切，可改善臨床癥狀，促進(jìn)胰酶分泌，緩解炎癥反應(yīng)程度，藥物安全性良好。

Objective To investigate the clinical efficacy of Yidanyan Mixture combined with Somatostatin for injection in treatment of acute pancreatitis. Methods Patients (83 cases) with acute pancreatitis in Nanyang Central Hospital from April 2019 to June 2021 were randomly divided into the control group (40 cases) and the treatment group (41 cases). Patients in the control group were iv administered with Somatostatin for injection, 3 mg added into normal saline 50 mL, continuous intravenous pumping, speed 250 μg/h, once daily. Patients in the treatment group were po administered with Yidanyan Mixture on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and the disappearance time of symptoms and the serum levels of lipase, amylase, HMGB1, DAO, and IL-35 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 92.68%, the total effective rate of the control group was 75.00%, and there was a significant difference between two groups (P<0.05). After treatment, the disappearance time of high fever, abdominal pain, abdominal distension, nausea, and vomiting in the treatment group was shorter than that in the control group (P<0.05). After treatment, the levels of lipase and amylase in two groups were significantly decreased (P<0.05), and the levels of lipase and amylase in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of HMGB1, DAO, and IL-35 in two groups were significantly decreased (P<0.05). The levels of HMGB1, DAO, and IL-35 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Yidanyan Mixture combined with Somatostatin for injection is effective in treatment of acute pancreatitis, which can improve the efficiency of clinical symptoms, promote the secretion of pancreatin, and alleviate the degree of inflammation, with good safety.

R975

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20191164）